论文部分内容阅读
将118例2型DN病人随机分为对照组(福辛普利)和治疗组(福辛普利+Lipo PGE1)。比较治疗后6周UAER、Scr、BUN等指标的变化。结果①治疗和对照组UAER均显著下降(P<0.05,P<0.01,治疗组比对照组下降更为明显(P<0.05),②治疗组Scr显著下降(P<0.05),而对照组无明显改变。③两组BUN、FPG、MPA、TC和TG均无明显变化。结论前列腺素E1和福辛普利联合治疗能有效减少早期DN和肾功能正常的临床DN病人的蛋白尿,改善肾功能。
118 patients with type 2 DN were randomly divided into control group (fosinopril) and treatment group (fosinopril + Lipo PGE1). The changes of UAER, Scr and BUN after 6 weeks of treatment were compared. Results ① The UAER of the treatment group and the control group were significantly decreased (P <0.05, P <0.01, the treatment group decreased more significantly than the control group (P <0.05), ② The treatment group Scr decreased significantly (P <0.05) There was no significant change in BUN, FPG, MPA, TC and TG.Conclusion Prostaglandin E1 combined with fosinopril can effectively reduce proteinuria in early DN and clinical DN patients with normal renal function and improve renal Features.